Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522592-29-00

Enrollment

Registered

2026-02-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary atherosclerotic status in women with postmenopausal osteoporosis

Brief summary

Change in the coronary CT score adapted according to the CCTA-Leaman method after 12 months of therapy.

Detailed description

Change in scores: Segment Involvement Score (SIS) and Segment Stenosis Score (SSS) between V1 and V3, Measurement of biomarkers at V1 and their correlation with changes in coronary scores: Sclerostin, Lipoprotein-Associated Phospholipase A2, Myeloid-Related Protein 8 and 14, and Monocyte Chemoattractant Protein 1 (MCP-1).

Interventions

DRUGEVENITY 105 mg solution for injection in pre-filled pen

DRUGProlia 60 mg solution for injection in pre-filled syringe

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in the coronary CT score adapted according to the CCTA-Leaman method after 12 months of therapy.	—

Secondary

Measure	Time frame
Change in scores: Segment Involvement Score (SIS) and Segment Stenosis Score (SSS) between V1 and V3, Measurement of biomarkers at V1 and their correlation with changes in coronary scores: Sclerostin, Lipoprotein-Associated Phospholipase A2, Myeloid-Related Protein 8 and 14, and Monocyte Chemoattractant Protein 1 (MCP-1).	—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 24, 2026